France’s biotech ecosystem: science, capital and scale

About this episode

The episode explores France's biotech ecosystem and the challenges in translating early innovation into scalable biotech investments.

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech. Host ⁠Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Ksenija Pavletic , Partner and Chief Commercial Officer, Jeito Capital Thierry Laugel , Managing Partner, Kurma Partners Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

People in this episode

Host: Jennifer C. Smith-Parker

Guests: Ksenija Pavletic, Thierry Laugel

Topics covered

• biotech ecosystem
• life sciences
• investment
• innovation
• scalability

Keywords

• biotech
• investment
• France
• life sciences
• innovation
• scalability
• Jeito Capital
• Kurma Partners

Mentioned in this episode

Organizations: Jeito Capital, Kurma Partners

Places: France

More episodes of BioSpace

• Portugal, Spain and the new biotech frontier · June 10, 2026 · 21 min
• Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence · June 10, 2026 · 25 min
• Rethinking hair loss treatment · June 3, 2026 · 22 min
• ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck · June 3, 2026 · 27 min
• Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds · May 27, 2026 · 25 min
• Inside Germany’s biotech capital infrastructure and innovation engine · May 21, 2026 · 23 min